Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $42.92
    -0.81 (-1.85%)

    Market Cap: $823.43M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Rigel Pharmaceuticals Inc (RIGL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rigel Pharmaceuticals (RIGL) has a market cap of $823.43M and an enterprise value of $784.02M. It kept 106.59% of revenue as net income over the last 12 months. Its share count is up 3.73% from a year earlier.

    Total Valuation

    Enterprise value is 4.79% below the market cap, as cash exceeds debt.

    Market Cap$823.43M
    Enterprise Value$784.02M
    Latest price (Nov 17, 2026)$42.92

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.91% in the quarter ended Sep 30, 2026 and grew 3.11% a year over 2 years.

    Shares Outstanding18.71M
    Shares Change (YoY)+3.73%
    Shares Change (QoQ)+0.91%
    Share Count Growth (2Y CAGR)+3.11%

    Valuation Ratios

    Sales and book value multiples are 2.8x and 1.8x. Its year-end P/E ranged from 6.6x to 378.6x from 2021 to 2025.

    P/E Ratio13.9x
    Forward P/E14.5x
    P/S Ratio2.8x
    Forward P/S2.7x
    P/B Ratio1.8x
    P/TBV Ratio2.3x
    P/OCF Ratio9.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 9.7x EBITDA.

    EV / Earnings2.6x
    EV / Sales2.7x
    EV / EBITDA9.7x
    EV / EBIT10.4x

    Price Statistics

    The stock is up 2.34% over 52 weeks and trades 9.16% below its 50-day average.

    Beta (1Y)1.08
    52-Week Change+2.34%
    1-Month Change-8.13%
    3-Month Change-8.60%
    6-Month Change+51.66%
    5-Year Change+52.71%
    10-Year Change+97.35%
    Total Return (1Y)+2.34%
    Total Return (3Y CAGR)+68.43%
    Total Return (5Y CAGR)+7.79%
    Return vs SPY (1Y)-18.70%
    Max Drawdown (1Y)-50.08%
    Max Drawdown (3Y)-50.76%
    Sharpe Ratio (1Y)-0.14
    Correlation with SPY (1Y)0.27
    50-Day Average$47.25
    200-Day Average$37.66
    52-Week Range$24.95 to $52.60
    RSI (14 Days)40.9
    Average Volume (20 Days)247.41K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.39x current liabilities, and total debt is 0.02x shareholder equity.

    Current Ratio2.39x
    Quick Ratio2.19x
    Debt / Equity0.02x
    Debt / EBITDA0.09x
    Interest Coverage18.17x

    Returns and Efficiency

    Return on invested capital is 16.74% over the last 12 months, against a 5-year average of -39.33%.

    Return on Equity (ROE)69.02%
    Return on Assets (ROA)58.64%
    Return on Invested Capital (ROIC)16.74%
    Return on Capital Employed (ROCE)17.02%
    ROA (5Y Average)1.28%
    ROIC (5Y Average)-39.33%
    Asset Turnover0.75x
    Inventory Turnover1.98x
    Receivables Turnover5.12x
    Cash Conversion Cycle161 days

    Scores

    RIGL has an Altman Z-Score of 4.77, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score4.77
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $288.21M over the last 12 months is up 2.18% from the 12 months before.

    Revenue$288.21M
    Revenue Growth (YoY)+2.18%
    Gross Profit$258.34M
    Operating Income$75.73M
    Pretax Income$75.36M
    Net Income$307.19M
    EBITDA$79.09M
    EBIT$75.73M
    Reported EPS (TTM)$3.09

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.96% of the $523.88M in total assets.

    Cash and Equivalents$46.65M
    Total Debt$7.24M
    Net Cash$39.41M
    Net Cash Per Share$2.11
    Working Capital$109.75M
    Shareholder Equity$445.11M
    Book Value Per Share$23.79
    Tangible Book Value$350.52M
    Tangible Book Per Share$18.73
    Total Assets$523.88M
    Total Liabilities$78.77M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$89.92M
    FCF Per Share$4.81
    Depreciation and Amortization$4.32M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 26.28%, against a 5-year average of -3.19%.

    Gross Margin89.64%
    Operating Margin26.28%
    Pretax Margin26.15%
    Net Margin106.59%
    EBITDA Margin27.44%
    EBIT Margin26.28%
    Gross Margin (5Y Average)94.93%
    Operating Margin (5Y Average)-3.19%
    Net Margin (5Y Average)10.46%

    Growth

    Revenue grew 34.76% a year over 3 years.

    Revenue Growth (3Y CAGR)+34.76%
    Revenue Growth (5Y CAGR)+22.06%

    Revenue and profit by year

    Dividends and Yields

    RIGL does not pay a dividend.

    Earnings Yield7.19%
    Buyback Yield-0.33%
    Shareholder Yield-0.33%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jun 27, 2024.

    Last Split DateJun 27, 2024
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 7 similar companies, RIGL has the 6th highest P/S.

    P/S Ratio2.8x vs 13.1x median
    ROIC16.74% vs -14.91% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.18% vs -61.26% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 12.80% and EPS growth at -14.21% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+12.80%
    EPS Growth Forecast (2Y CAGR)-14.21%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RIGL

    What is RIGL's market cap?

    Rigel Pharmaceuticals has a market cap of $823.43M. Its enterprise value, which adds debt and subtracts cash, is $784.02M.

    What is RIGL's P/E ratio?

    Rigel Pharmaceuticals has a trailing P/E ratio of 13.9x and a forward P/E of 14.5x.

    How many shares of RIGL are outstanding?

    Rigel Pharmaceuticals has 18.71M shares outstanding. The count is up 3.73% from a year earlier.

    Does RIGL pay a dividend?

    No. Rigel Pharmaceuticals does not pay a dividend.

    How much debt does RIGL have?

    Rigel Pharmaceuticals has $7.24M of total debt and $46.65M of cash and equivalents, a net cash position of $39.41M.